Acquisition Opportunity Brightech International was acquired by Everest Clinical Research Services in December 2022, indicating potential integration opportunities, portfolio alignment with larger CRO capabilities, and possible cross-sell or partnership avenues with Everest's client base and global footprint.

Mid-Market CRO Operating with 11-50 employees and annual revenue in the 25–50 million range, Brightech positions as a mid-market CRO with scalable clinical data solutions that can be attractive to sponsors seeking flexible, cost-efficient partnerships without engaging large mega-CROs.

Clinical Data Focus Specialization in biostatistics, SAS programming, data management, medical writing, regulatory strategy, and CDISC services, plus a proprietary eClinical Suite (CIMS), signals strong capabilities for sponsors needing end-to-end data management and regulatory submission readiness.

Long-Term Relationships A track record of supporting 25+ long-term clients and multiple NDA approvals suggests reliability and relationship depth, presenting opportunities for renewals, additional studies, and expansion into full-service offerings for existing clients.

Growth Signals Recent branding updates and a history of growth-focused milestones, along with a revenue profile aligned to mid-market CROs, indicate readiness to scale services, upsell advanced analytics, and expand into additional therapeutic areas or trial designs.